Impact of autofluorescence for detection of parathyroid glands during thyroidectomy on postoperative parathyroid hormone levels: parallel multicentre randomized clinical trial

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Who Took Part

Patients were randomized 1 : 1 and were blinded to the group allocation.

How the Study Was Run

The researchers set it up as a randomized, multicenter and parallel-group study.

The participants were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

Running at several centres spread the Parathyroid Hormone (PTH 1-84) study over different clinics and patient groups.

The Parathyroid Hormone (PTH 1-84) group and the comparison group ran side by side rather than switching.

This parallel multicentre RCT investigated the use of Fluobeam® LX to visualize the parathyroid glands by autofluorescence during total thyroidectomy compared with no use.

There was no restriction on the indication for surgery.

The hypothesis was that autofluorescence enables identification and protection of the parathyroid glands during thyroidectomy.

The primary endpoint was the rate of low parathyroid hormone (PTH) levels the day after surgery.

What Was Measured

Topics PubMed links to this paper include Parathyroid Glands, Thyroidectomy, Parathyroid Hormone, Hypoparathyroidism, Lymph Nodes, Postoperative Complications and Hypocalcemia.

What This Means in Plain Language

The paper is a randomized, multicenter and parallel-group study of Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (The British journal of surgery), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.